Carboplatin/Nedaplatin

PreclinicalSmall molecule

WWigen Biomedicine Technology (Shanghai) Co., Ltd.

Carboplatin/Nedaplatin is one of 82 small molecule programs targeting Advanced Solid Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsRecruiting

Solid TumorRecruiting

Advanced Solid TumorsPreclinical

Recruiting

Solid TumorPreclinical

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 2

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 3

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 4

Soc

Pfizer

Preclinical

1 5

Carboplatin AUC-5

Merck & Co.

Preclinical

1 6

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

2 7

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Preclinical

1 8

Immune Checkpoint Inhibitors

PPeking Union Medical College Hospital

Preclinical

1 9

Interleukin 2

EEssen Biotech

Preclinical

1 10

SHR-A2102

Shanghai Hengrui Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Solid Tumor

NCT06953323

Clinical

Trials by Indication[1]

Esophageal Carcinoma1 trial

Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma

Unknown status·—·Phase 1/2·NCT05777707·89 enrolled

Solid Tumor1 trial

A Dose-escalation, Dose-expansion and Efficacy Extension Phase I/II Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of WJB001 Combination Therapy in Patients With Advanced Solid Tumors

Recruiting·WWigen Biomedicine Technology (Shanghai) Co., Ltd.·Preclinical·NCT06953323·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Carboplatin/Nedaplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboplatin/Nedaplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboplatin/Nedaplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wigen Biomedicine Technology (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWigen Biomedicine Technology (Shanghai) Co., Ltd.

Carboplatin/Nedaplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Esophageal Carcinoma1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News